Disease landscape
Parkinson's disease
Severe restrictions in access to Parkinson’s disease treatment and diagnosis have been identified in the Visegrád (V4) countries as measured in the GAP score. Results vary moderately from country to country and the difference between the highest and the lowest scoring country is about 11 points. The main reason for the highly unfavourable assessment is extremely limited access to the newest registered drugs due to the lack of reimbursement, which results in 0% share of patients treated with the newest Parkinsons’ disease molecules or formulations.
Cross-Country
General GAP for Parkinson's disease
Compliance with guidelines
All the 3 most recently authorised drugs in Parkinson’s disease fall into the groups of drugs recommended by clinical guidelines. Nevertheless those drugs are generally not reimbursed in V4 region: one drug is covered with reimbursement in Czechia and one in Hungary only.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
parkinson’s disease prevalence
Drug access
Number of patients treated (2021)
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for Parkinson’s disease drugs in the V4 countries is almost 6.3 years. The difference between the shortest and the longest mean time to reimbursement among the countries is below 0.5 year.
- The three most recently authorised drugs in Parkinson’s disease were not reimbursed in V4 states in 2021 both in regular reimbursement and early access program. The proportion of patients in the target group treated with these drugs is then 0% in all V4 countries.
- Population burden in V4 states is much lower than the European Union average. An strongly increasing trend of DALY values was observed in V4 states in past years.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).